Morgan Stanley Corbus Pharmaceuticals Holdings, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.11 - $5.46 $6,755 - $335,298	-61,410 Reduced 42.4%	83,430 $9,000
Q3 2022 Nov 14, 2022	BUY	$0.17 - $5.31 $1,870 - $58,431	11,004 Added 8.22%	144,840 $23,000
Q2 2022 Oct 27, 2022	BUY	$0.21 - $0.53 $2,837 - $7,160	13,511 Added 11.23%	133,836 $35,000
Q2 2022 Aug 15, 2022	BUY	$0.21 - $0.53 $2,837 - $7,160	13,511 Added 11.23%	133,836 $35,000
Q1 2022 Oct 27, 2022	SELL	$0.32 - $0.67 $4,323 - $9,052	-13,511 Reduced 10.1%	120,325 $64,000
Q1 2022 May 13, 2022	SELL	$0.32 - $0.67 $627,747 - $1.31 Million	-1,961,711 Reduced 94.22%	120,325 $64,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.11 $352,654 - $652,411	-587,758 Reduced 22.02%	2,082,036 $1.28 Million
Q3 2021 Nov 15, 2021	BUY	$1.01 - $1.82 $2.7 Million - $4.86 Million	2,669,794 New	2,669,794 $2.72 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.